Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Post by lscfaon Sep 29, 2024 4:29pm
634 Views
Post# 36246166

CMS is incompetent

CMS is incompetent

NIV RECONSIDERATION: TRY-AND-FAIL RECOMMENDATION CAUSES CONCERNS 

Ronda BuhrmesterWASHINGTON – Industry stakeholders are concerned that a recommendation to require COPD patients to try and fail on respiratory assist devices before they can qualify for non-invasive ventilators will impede access for patients. 

The recommendation is part of a request to reconsider the national coverage determination for the use of non-invasive ventilators and respiratory assist devices for Medicare beneficiaries with COPD. 

It would be better to first deal with existing issues surrounding RAD devices and clarifying and simplifying their coverage, says Kim Brummett, senior vice president of regulatory affairs for AAHomecare. 

“A lot of patients are on NIV because it works for them and qualifying for a RAD is incredibly complicated,” she said. “Our biggest fear is that they are going to narrow the criteria and then we don’t have a revision to the RAD LCD and these patients are really caught between a rock and a hard place and can’t get anything.” 

The request to reconsider the NCD for the use of NIV and RAD was made by The Optimal Noninvasive Ventilation Medicare Access Promotion Technical Expert Panel (TEP), which comprises representatives from the American College of Chest Physicians, the American Academy of Sleep Medicine, the American Association for Respiratory Care, and the American Thoracic Society. 

The request also includes a recommendation for 24/7 clinical support, a mandate that could be difficult to meet, says Ronda Buhrmester, senior director of payer relations and reimbursement for VGM. 

“A lot of suppliers do that anyway when ventilators are involved but to mandate that is a different situation,” she said. “They are asking for RTs to be available to do clinical assessments, but there’s already a shortage of RTs in health care. And also, will we get reimbursed for that? We currently don’t.” 

While stakeholders say they are still digesting the request, which CMS published on Sept. 11 with a comment deadline of Oct. 11, they say it’s important to be aligned on the issue, within the industry and, to the extent that it’s possible, with other stakeholders. 

“We don’t want to get into wordsmithing the medical records and making it subjective criteria,” Brummett said. “Just make sure it’s objective criteria that everybody knows – the prescribers, the suppliers – whether the patient qualifies or not and to be conscientious of those patients who are on NIV that may not meet coverage criteria in a revision.”


<< Previous
Bullboard Posts
Next >>